flow trial semaglutide kidney outcomes 2024 nejm hazard ratio 0.76 Study: Semaglutide slowed progression of CKD, cut cardiovascular events, mortality risk 🚨 Journal Club: FLOW Trial – In the FLOW trial, researchers

This results in cell and skin renewal

No other GLP-1 program offers this We believe you'll reach your goal with us

Achieving euglycaemia in women with gestational diabetes mellitus: Current options for screening, diagnosis and treatment

A new long-acting analogue based on liquid crystal technology, CAM2029, was shown by Diego Ferone and coauthors to be highly effective, and indicating that self- or partner-injection can be used, as for lanreotide autogel. That study, Octreotide subcutaneous depot for acromegaly: A randomized, double-blind, placebo-controlled phase 3 trial, ACROINNOVA 1 published in May

When choosing between these treatments, its important to weigh the cost against the expected benefits and outcomes